|
|
|
|
|||||
|
|
|
DexCom, Inc. (NASDAQ:DXCM) is one of the best strong buy healthcare stocks to buy now. On July 16, Mizuho analyst Anthony Petrone raised the firm’s price target on DexCom, Inc. (NASDAQ:DXCM) to $100 from $95 while keeping an Outperform rating on the shares.
The rating update came with the firm adjusting price targets in the medical devices and diagnostics sector ahead of Q2 2025 earnings. DexCom, Inc. (NASDAQ:DXCM) is set to report its Q2 results on July 30.
DexCom, Inc. (NASDAQ:DXCM) is a medical device company that manufactures continuous glucose monitoring (CGM) systems to allow real-time health management control. Specializing in diabetes care technology, the company helps improve and simplify diabetes management worldwide.
It offers various medical devices and products, including Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE.
While we acknowledge the potential of DXCM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
| Jul-25 | |
| Jul-24 | |
| Jul-24 | |
| Jul-23 | |
| Jul-21 | |
| Jul-20 | |
| Jul-17 | |
| Jul-17 | |
| Jul-15 | |
| Jul-15 | |
| Jul-14 | |
| Jul-09 | |
| Jul-07 | |
| Jul-06 | |
| Jul-03 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite